Genetic susceptibility to type 2 diabetic nephropathy in human and animal models

Nephrology

Volumn 10, Issue SUPPL. 2, 2005, Pages

  Gohda, Tomohito ^a   Tanimoto, Mitsuo ^a   Watanabe Yamada, Kaori ^a   Matsumoto, Masakazu ^a   Kaneko, Shigeru ^a   Hagiwara, Shinji ^a   Shiina, Kenji ^a   Shike, Toshihide ^a   Funabiki, Kazuhiko ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Association study; Diabetic nephropathy; Differential display; Genetics; Microarray; Polymorphism; QTL analysis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL MODEL; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; DNA POLYMORPHISM; ETHNIC DIFFERENCE; FAMILIAL INCIDENCE; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEREDITY; HUMAN; KIDNEY FAILURE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SIBLING; STRAIN DIFFERENCE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; QUANTITATIVE TRAIT LOCI;

EID: 28544438569     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00452.x     Document Type: Conference Paper

References (23)

1. Patient Registration Committee Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2002). Ther Apher Dial 2004; 8: 358-82.
2. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am. J. Med. 1985; 78: 785-94.
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 1984; 102: 520-6.
4. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996; 39: 940-5.
5. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 438-43.
6. Stahn RM, Gohdes D, Valway SE. Diabetes and its complications among selected tribes in North Dakota, South Dakota, and Nebraska. Diabetes Care 1993; 16: 244-7.
7. Haffner SM, Mitchell BD, Pugh JA et al. Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM. Diabetes Care 1989; 12: 530-6.
8. Maeda S, Kikkawa R, Haneda M et al. Reduced activity of renal angiotensin-converting enzyme in streptozotocin-induced diabetic rats. J. Diabetes Complications 1991; 5: 225-9.
9. Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. 1992; 51: 197-205.
10. Cambien F, Costerousse O, Tiret L et al. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994; 90: 669-76.
11. Ha SK, Lee SY, Park HS et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol. Dial. Transplant. 2000; 15: 1617-23.
12. Tomino Y, Makita Y, Shike T et al. Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron 1999; 82: 139-44.
13. Gohda T, Makita Y, Shike T et al. Association of the DD genotype and development of Japanese type 2 diabetic nephropathy. Clin. Nephrol. 2001; 56: 475-80.
14. Fujisawa T, Ikegami H, Kawaguchi Y et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53.
15. Ikeda H. KK mouse. Diabetes Res. Clin. Pract. 1994; 24: S313-6.
16. Reddi AS, Wehner H, Khan MY, Camerini-Davalos RA. Kidney disease in KK mice: structural, biochemical and functional relationships. Adv. Exp Med. Biol. 1988; 246: 135-45.
17. Shike T, Hirose S, Kobayashi M, Funabiki K, Shirai T, Tomino Y. Susceptibility and negative epistatic loci contributing to type 2 diabetes and related phenotypes in a KK/Ta mouse model. Diabetes 2001; 50: 1943-8.
18. Shike T, Gohda T, Tanimoto M et al. Chromosomal mapping of a quantitative trait locus for the development of albuminuria in diabetic KK/Ta mice. Nephrol. Dial. Transplant. 2005; 20: 879-85.
19. Klupa T, Malecki MT, Pezzolesi M et al. Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes 2000; 49: 2212-6.
20. Rahman ZS, Tin SK, Buenaventura PN et al. A novel susceptibility locus on chromosome 2 in the (New Zealand Black x New Zealand White) F1 hybrid mouse model of systemic lupus erythematosus. J. Immunol. 2002; 168: 3042-9.
21. Fan Q, Shike T, Shigihara T et al. Gene expression profile in diabetic KK/Ta mice. Kidney Int. 2003; 64: 1978-85.
22. Gohda T, Makita Y, Shike T et al. Identification of epistatic interaction involved in obesity using the KK/Ta mouse as a Type 2 diabetes model: is Zn-alpha2 glycoprotein-1 a candidate gene for obesity? Diabetes 2003; 52: 2175-81.
23. Sanchez LM, Chirino AJ, Bjorkman P. Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. Science 1999; 283: 1914-9.